Reshaping
the landscape
of treating chronic venous insufficiency

InterVene Inc. is a trailblazing medical device company focused on reshaping the landscape of treating chronic post-thrombotic venous occlusions and obstructions - the severe late term complications arising from deep vein thrombosis (DVT) and chronic venous insufficiency (CVI).

InterVene Inc.

Introducing ChronusTM

A groundbreaking class of interventional technology, engineered to address chronic venous issues comprehensively.

ChronusTM is designed to efficiently de-bulk and recanalize chronic post-thrombotic venous occlusions and obstructions. 

CAUTION: Investigational device.  Limited by Federal (United States) law to investigate in US.  The ChronusTM is not approved for sale worldwide.  This device is not FDA cleared or approved for clinical use, and is currently in the development stage.

Chronus 4

What is
Chronic Venous Insufficiency?

Chronic Venous Insufficiency (CVI) is a condition that occurs when the veins in the legs are unable to pump blood back to the heart effectively.

This impairment in venous blood flow can lead to symptoms such as leg swelling, pain, and skin changes (pigmentation and/or ulcers).

CVI often develops as a late-stage complication of conditions like deep vein thrombosis (DVT), where blood clots (thrombus) in the deep veins of the legs hinder normal circulation.

Treatment typically involves lifestyle modifications, compression therapy, and medications to alleviate symptoms and improve overall venous function.

What is
Chronic Post-Thrombotic Venous Obstruction?

After a blood clot is gone (post-thrombotic), it can leave scar tissue that damages the vein.  Unlike thrombus that can be dissolved or removed, collagen based scar tissue remains in place and can continue to grow leading to the vein being obstructed (severely limiting flow) or occluded (completely closed off).

These obstructions or occlusions create venous blood flow stasis and stagnant, no flow inflammation, resulting in severe pain and ulcers.

Chronic post-thrombotic venous obstructions and occlusions can form even after treatment with DVT treatment and/or venous stenting as evidenced by the recent awareness of poor stent patency and rapid lumen loss and the need for multiple reinterventions.

Prevalence & Impact:
Approximately 9.4 million Americans grapple with moderate to severe CVI. Symptoms may encompass leg swelling, pain, skin changes, and the emergence of leg ulcers.

Current Standard of Care:
Palliative measures for chronic venous flow obstruction include compression therapy, leg elevation, and local wound care. Severe CVI is often treated with venous stenting.

Progression and Consequences:
The most severe CVI patients are universally postthrombotic and the majority will have chronic venous obstruction or occlusion.

20-60% of patients will need a reintervention depending on the severity of their venous disease.

In-House Venous Incubator

VeinLab

The company’s core competency lies in its comprehensive, in-house capabilities, covering every facet of the product development lifecycle.

From cutting-edge Research and Development (R&D) initiatives to precision manufacturing, rigorous Quality Systems, and meticulous attention to Clinical Research and Regulatory Affairs, InterVene maintains control over every aspect of its operations.

This integrated approach not only ensures a seamless and efficient development process but also allows for swift adaptation to emerging trends and unmet needs in the rapidly emerging venous field.

InterVene’s team of venous experts has developed a strong pipeline to expand the  product portfolio.